Somaxon Sues Actavis Over Generic Silenor

Law360, New York (May 10, 2011, 7:22 PM EDT) -- Somaxon Pharmaceuticals Inc. hit Actavis Inc. with a patent infringement suit in Delaware on Monday over Actavis' bid for regulatory approval to market a generic version of Somaxon's insomnia drug Silenor.

Somaxon alleges that Actavis’ submission of an abbreviated new drug application for a generic version of Silenor constituted an infringement of Somaxon's U.S. Patent Number 7,915,307, issued on March 29 and titled "Methods of improving pharmacokinetics of doxepin.”

The suit, lodged against Actavis and subsidiary Actavis Elizabeth LLC, comes more than three months after Somaxon...
To view the full article, register now.